Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy

Early Phase 1UnknownNCT05828238

Affiliated Hospital of Jiangnan University10 enrolled

Overview

This is a single arm study to determining the value of apoptotic molecular probe SF-DEVD-2 in the early evaluation of tumor efficacy and comparing it head-to-head wihe 18F-FDG(18F-2-fluoro-2-deoxy-D-glucose)

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Breast Cancer Stage II Breast Cancer Stage III Solid Tumor

Interventions

[18F]SF-DEVD-2DRUG

Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2

[18F]-FDGDRUG

Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients voluntarily signed informed consent; 2. Age18-70, male or female; 3. Diagnosed with stage 2 or 3 breast cancer 4. Solid tumors、masses larger than 2cm with lymph node metastasis 5. Pathology is HER3+、triple negative patients 6. Patients to be treated with neoadjuvant chemotherapy Exclusion Criteria: 1. Age greater than or equal to 70 years old 2. Abnormal liver and kidney function (more than five times the normal value) 3. Diagnosis level of breast cancer stage 4 or second time tumor patients

Locations (1)

Affiliated Hospital of Jiangnan University

Wuxi, Jiangsu, China

RECRUITING

Outcomes

Primary Outcomes

Evaluation of tissue distribution of [18F]-DEVD-2

Biodistribution of \[18F\] -DEVD-2 evaluated by the maximum standardized uptake value（SUVmax) in various organs during repeated \[18F\]-DEVD scans will be reported.

Time frame: 7 days

Central Contacts

Chunjing Yu

CONTACT

15312238622 ycj_wxd1978@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.